NUVB Insider Trading

Insider Ownership Percentage: 5.07%
Insider Buying (Last 12 Months): $1,985,500.47
Insider Selling (Last 12 Months): $0.00

Nuvation Bio Insider Trading History Chart

This chart shows the insider buying and selling history at Nuvation Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10M-$5M$0$5M$10MTotal Insider BuyingTotal Insider Selling

Nuvation Bio Share Price & Price History

Current Price: $1.82
Price Change: Price Decrease of -0.055 (-2.94%)
As of 03/28/2025 04:59 PM ET

This chart shows the closing price history over time for NUVB up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$1.81Closing price on 03/29/25:

SEC Filings (Institutional Ownership Changes) for Nuvation Bio (NYSE:NUVB)

61.67% of Nuvation Bio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at NUVB by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$56Mbought$4.67MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$40M-$20M$0$20M$40MTotal InflowsTotal Outflows
Nuvation Bio logo
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.
Read More on Nuvation Bio

Today's Range

Now: $1.82
Low: $1.80
High: $1.89

50 Day Range

MA: $2.19
Low: $1.82
High: $2.77

52 Week Range

Now: $1.82
Low: $1.71
High: $3.97

Volume

1,431,289 shs

Average Volume

1,942,415 shs

Market Capitalization

$614.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.47

Who are the company insiders with the largest holdings of Nuvation Bio?

Nuvation Bio's top insider shareholders include:
  1. Xiangmin Cui (Director)
  2. Kim D Blickenstaff (Director)
  3. Robert Mashal (Director)
Learn More about top insider investors at Nuvation Bio.

Who are the major institutional investors of Nuvation Bio?

Nuvation Bio's top institutional shareholders include:
  1. FMR LLC — 13.46%
  2. Vanguard Group Inc. — 4.67%
  3. Geode Capital Management LLC — 1.47%
  4. MPM Bioimpact LLC — 1.24%
  5. Millennium Management LLC — 0.74%
  6. Northern Trust Corp — 0.62%
Learn More about top institutional investors of Nuvation Bio stock.

Which institutional investors are selling Nuvation Bio stock?

During the last quarter, NUVB stock was sold by these institutional investors:
  1. Renaissance Technologies LLC
  2. Dimensional Fund Advisors LP
  3. Federated Hermes Inc.
  4. JPMorgan Chase & Co.
  5. Assenagon Asset Management S.A.
  6. Squarepoint Ops LLC
  7. XTX Topco Ltd
  8. Bank of America Corp DE

Which institutional investors are buying Nuvation Bio stock?

During the last quarter, NUVB stock was acquired by institutional investors including:
  1. FMR LLC
  2. Vanguard Group Inc.
  3. MPM Bioimpact LLC
  4. Millennium Management LLC
  5. Geode Capital Management LLC
  6. Algert Global LLC
  7. Northern Trust Corp
  8. Charles Schwab Investment Management Inc.
In the last year, these company insiders have bought Nuvation Bio stock:
  1. Xiangmin Cui (Director)
  2. Kim D Blickenstaff (Director)
  3. Robert Mashal (Director)
Learn More investors buying Nuvation Bio stock.